Metabolomics in Personalized Medicine

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Advances in Metabolomics".

Deadline for manuscript submissions: 30 November 2025 | Viewed by 395

Special Issue Editor


E-Mail Website
Guest Editor
Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Science, Jacksonville, FL 32224, USA
Interests: vascular zebrafish; cardiovascular disease; metabolic; disease models; molecular biology; cardiomyopathy; myocardial infarction
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Metabolomics is pivotal in advancing personalized medicine. Unlike static genetic information, metabolomic profiles offer a dynamic and integrative view of an individual’s physiological state, influenced by genetics, the environment, diet, lifestyle, and the microbiome. This capacity to capture real-time biochemical changes makes metabolomics particularly significant in identifying early disease biomarkers, stratifying patients, predicting drug responses, and monitoring therapeutic outcomes. The implementation of high-throughput technologies such as mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy offers deeper insights into complex metabolic networks and their relevance to human health and disease. As precision medicine continues to evolve, metabolomics can potentially bridge the gap between molecular diagnostics and tailored clinical care. This Special Issue aims to present recent developments in metabolomic technologies and their applications across various areas of personalized medicine. We welcome contributions that explore methodological innovations, clinical applications, and interdisciplinary approaches that harness metabolomics to improve diagnosis, treatment, and overall healthcare outcomes.

Dr. Angom Ramcharan Singh
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • metabolomics
  • personalized medicine
  • biomarkers
  • precision health
  • disease stratification
  • metabolic profiling
  • NMR spectroscopy
  • mass spectrometry
  • therapeutic response
  • systems biology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 2743 KiB  
Article
The Causal Role of the Gut Microbiota–Plasma Metabolome Axis in Myeloproliferative Neoplasm Pathogenesis: A Mendelian Randomization and Mediation Analysis
by Hao Kan, Ka Zhang, Aiqin Mao and Li Geng
Metabolites 2025, 15(8), 501; https://doi.org/10.3390/metabo15080501 - 28 Jul 2025
Viewed by 274
Abstract
Background: Myeloproliferative neoplasms (MPN), a group of chronic hematologic neoplasms, are driven by inflammatory mechanisms that influence disease initiation and progression. Emerging evidence highlights the gut microbiome and plasma metabolome as pivotal immunomodulators, yet their causal roles in MPN pathogenesis remain uncharacterized. Methods: [...] Read more.
Background: Myeloproliferative neoplasms (MPN), a group of chronic hematologic neoplasms, are driven by inflammatory mechanisms that influence disease initiation and progression. Emerging evidence highlights the gut microbiome and plasma metabolome as pivotal immunomodulators, yet their causal roles in MPN pathogenesis remain uncharacterized. Methods: We conducted a two-sample Mendelian randomization (MR) analysis to systematically evaluate causal relationships between 196 gut microbial taxa, 526 plasma metabolites, and MPN risk. Instrumental variables were derived from genome-wide association studies (GWASs) of microbial/metabolite traits. Validation utilized 16S rRNA sequencing data from NCBI Bioproject PRJNA376506. Mediation and multivariable MR analyses elucidated metabolite-mediated pathways linking microbial taxa to MPN. Results: Our MR analysis revealed that 7 intestinal taxa and 17 plasma metabolites are causally linked to MPN. External validation confirmed the three taxa’s differential abundance in MPN cohorts. Mediation analysis revealed two mediated relationships, of which succinylcarnitine mediated 14.5% of the effect, and lysine 27.9%, linking the Eubacterium xylanophilum group to MPN. Multivariate MR analysis showed that both succinylcarnitine (p = 0.004) and lysine (p = 0.040) had a significant causal effect on MPN. Conclusions: This study identifies novel gut microbiota–metabolite axes driving MPN pathogenesis through immunometabolic mechanisms. The validated biomarkers provide potential therapeutic targets for modulating inflammation in myeloproliferative disorders. Full article
(This article belongs to the Special Issue Metabolomics in Personalized Medicine)
Show Figures

Figure 1

Back to TopTop